Medical Market Report

Global Passive Transdermal Drug Delivery Market By Type (Microfluidics, and Smart Pill Technology (SPT)), By Application (Clinic, Hospital, and Others), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029

  • 139361
  • 18-Dec
  • PDF/PPT/Word
  • ★ ★ ★ ★ ★
    ★ ★ ★ ★ ★
  • Report Details

    Global Passive Transdermal Drug Delivery Market is estimated to be valued US$ XX.X million in 2019. The report on Passive Transdermal Drug Delivery Market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, etc. for the forecast year up to 2029. The global passive transdermal drug delivery market is segmented on the basis of Type, Application, and geography.

    Europe market was valued at US$ XX.X million in 2018 and is projected to reach US$ XX.X million in 2029, and register a CAGR of X.X% during the forecast period, according to a new Market.us (Prudour Research) study.

    Passive Transdermal Drug Delivery Market Scope:

    By type, the market is segmented into Microfluidics, and Smart Pill Technology (SPT). By Application, the market is divided into Clinic, Hospital, and Others.
    Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include 3M, Actavis Inc., Bayer AG, Boehringer Ingelheim GmbH, Corium International Inc., Echo Therapeutics Inc., GlaxoSmithKline plc, Johnson & Johnson (Janssen Pharmaceuticals Inc.), Mylan N.V., Novartis AG, Noven Pharmaceuticals Inc., and Transdermal Corp..

    Key Market Segments

    Type

    Microfluidics

    Smart Pill Technology (SPT)

    Application

    Clinic

    Hospital

    Others

    Key Market Players included in the report:

    3M

    Actavis Inc.

    Bayer AG

    Boehringer Ingelheim GmbH

    Corium International Inc.

    Echo Therapeutics Inc.

    GlaxoSmithKline plc

    Johnson & Johnson (Janssen Pharmaceuticals Inc.)

    Mylan N.V.

    Novartis AG

    Noven Pharmaceuticals Inc.

    Transdermal Corp.

    Reasons to Get this Report:

    In an insight outlook, this research report has dedicated to several quantities of analysis – industry research (global industry trends) and Passive Transdermal Drug Delivery Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of Passive Transdermal Drug Delivery Market; high-growth regions; and market drivers, restraints, and also market chances.
    The analysis covers Passive Transdermal Drug Delivery Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Passive Transdermal Drug Delivery Market across sections such as also Application and representatives.
    Additionally, the analysis also has a comprehensive review of the crucial players on the Passive Transdermal Drug Delivery Market together side their company profiles, SWOT analysis, latest advancements, and business plans.

    The analysis objectives of the report are:

    To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
    To know the Passive Transdermal Drug Delivery Market by pinpointing its many subsegments.
    To profile the important players and analyze their growth plans.
    To endeavor the amount and value of Passive Transdermal Drug Delivery sub-markets, depending on key regions (various vital states).
    To analyze Passive Transdermal Drug Delivery Market concerning growth trends, prospects, and also their participation in the entire sector.
    To examine and study the Passive Transdermal Drug Delivery Market size (volume & value) from the company, essential regions/countries, products, and Application, background information from 2013 to 2018, and also prediction to 2029.
    Primary worldwide Passive Transdermal Drug Delivery Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
    To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market.

  • Table Of Content 
    1. Passive Transdermal Drug Delivery Market Introduction
    

    1.1. Definition
    
1.2. Taxonomy
    
1.3. Research Scope
    

    2. Executive Summary
    

      2.1. Key Findings by Major Segments
    
  2.2. Top strategies by Major Players
    

    3. Global Passive Transdermal Drug Delivery Market Overview
    

    3.1. Passive Transdermal Drug Delivery Market Dynamics
    

        3.1.1. Drivers
    
    3.1.2. Opportunities
    
    3.1.3. Restraints
    
    3.1.4. Challenges
    

      3.2. PESTLE Analysis
    
  3.3. Opportunity Map Analysis
    
  3.4. PORTER’S Five Forces Analysis
    
  3.5. Market Competition Scenario Analysis
    
  3.6. Product Life Cycle Analysis
    
  3.7. Opportunity Orbits
    
  3.8. Production Analysis by Region/Company
    
  3.9. Industry chain Analysis
    
  3.10. Marketing Strategy
    

    4. Global Passive Transdermal Drug Delivery Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
    

      4.1. Global Passive Transdermal Drug Delivery Market Analysis by Type: Introduction
    
  4.2. Market Size and Forecast by Region
    
  4.3. Microfluidics
    

      4.4. Smart Pill Technology (SPT)
    

    5. Global Passive Transdermal Drug Delivery Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
    

      5.1. Global Passive Transdermal Drug Delivery Market Analysis by Application: Introduction
    
  5.2. Market Size and Forecast by Region
    
  5.3. Clinic
    

      5.4. Hospital
    

      5.5. Others
    

    6. Global Passive Transdermal Drug Delivery Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
    

      6.1. North America
    

        6.1.1. North America Passive Transdermal Drug Delivery Market: Regional Trend Analysis
    

         6.1.1.1. US
    
     6.1.1.2. Canada
    
     6.1.1.3. Mexico
    

      6.2.1. Europe
    

        6.2.1. Europe Passive Transdermal Drug Delivery Market: Regional Trend Analysis
    

         6.2.1.1. Germany
    
     6.2.1.2. France
    
     6.2.1.3. UK
    
     6.2.1.4. Russia
    
     6.2.1.5. Italy
    
     6.2.1.6. Spain
    
     6.2.1.7. Rest of Europe
    

      6.3. Asia-Pacific
    

        6.3.1. Asia-Pacific Passive Transdermal Drug Delivery Market: Regional Trend Analysis
    

         6.3.1.1. China
    
     6.3.1.2. Japan
    
     6.3.1.3. Korea
    
     6.3.1.4. India
    
     6.3.1.5. Rest of Asia-Pacific
    

      6.4. Latin America
    

        6.4.1. Latin America Passive Transdermal Drug Delivery Market: Regional Trend Analysis
    

         6.4.1.1. Brazil
    
     6.4.1.2. Argentina
    
     6.4.1.3. Rest of Latin America
    

      6.5. Middle East and Africa
    

        6.5.1. Middle East and Africa Passive Transdermal Drug Delivery Market: Regional Trend Analysis
    

         6.5.1.1. GCC
    
     6.5.1.2. South Africa
    
     6.5.1.3. Israel
    
     6.5.1.4. Rest of MEA
    

    7. Global Passive Transdermal Drug Delivery Market Competitive Landscape, Market Share Analysis, and Company Profiles
    

      7.1. Market Share Analysis
    
  7.2. Company Profiles
    
  7.3. 3M
    

        7.3.1. Company Overview
    
    7.3.2. Financial Highlights
    
    7.3.3. Product Portfolio
    
    7.3.4. SWOT Analysis
    
    7.3.5. Key Strategies and Developments
    

      7.4. Actavis#Inc.
    

        7.4.1. Company Overview
    
    7.4.2. Financial Highlights
    
    7.4.3. Product Portfolio
    
    7.4.4. SWOT Analysis
    
    7.4.5. Key Strategies and Developments
    

      7.5. Bayer AG
    

        7.5.1. Company Overview
    
    7.5.2. Financial Highlights
    
    7.5.3. Product Portfolio
    
    7.5.4. SWOT Analysis
    
    7.5.5. Key Strategies and Developments
    

      7.6. Boehringer Ingelheim GmbH
    

        7.6.1. Company Overview
    
    7.6.2. Financial Highlights
    
    7.6.3. Product Portfolio
    
    7.6.4. SWOT Analysis
    
    7.6.5. Key Strategies and Developments
    

      7.7. Corium International#Inc.
    

        7.7.1. Company Overview
    
    7.7.2. Financial Highlights
    
    7.7.3. Product Portfolio
    
    7.7.4. SWOT Analysis
    
    7.7.5. Key Strategies and Developments
    

      7.8. Echo Therapeutics#Inc.
    

        7.8.1. Company Overview
    
    7.8.2. Financial Highlights
    
    7.8.3. Product Portfolio
    
    7.8.4. SWOT Analysis
    
    7.8.5. Key Strategies and Developments
    

      7.9. GlaxoSmithKline plc
    

        7.9.1. Company Overview
    
    7.9.2. Financial Highlights
    
    7.9.3. Product Portfolio
    
    7.9.4. SWOT Analysis
    
    7.9.5. Key Strategies and Developments
    

      7.10. Johnson & Johnson (Janssen Pharmaceuticals Inc.)
    

        7.10.1. Company Overview
    
    7.10.2. Financial Highlights
    
    7.10.3. Product Portfolio
    
    7.10.4. SWOT Analysis
    
    7.10.5. Key Strategies and Developments
    

      7.11. Mylan N.V.
    

        7.11.1. Company Overview
    
    7.11.2. Financial Highlights
    
    7.11.3. Product Portfolio
    
    7.11.4. SWOT Analysis
    
    7.11.5. Key Strategies and Developments
    

      7.12. Novartis AG
    

        7.12.1. Company Overview
    
    7.12.2. Financial Highlights
    
    7.12.3. Product Portfolio
    
    7.12.4. SWOT Analysis
    
    7.12.5. Key Strategies and Developments
    

      7.13. Noven Pharmaceuticals#Inc.
    

        7.13.1. Company Overview
    
    7.13.2. Financial Highlights
    
    7.13.3. Product Portfolio
    
    7.13.4. SWOT Analysis
    
    7.13.5. Key Strategies and Developments
    

      7.14. Transdermal Corp.
    

        7.14.1. Company Overview
    
    7.14.2. Financial Highlights
    
    7.14.3. Product Portfolio
    
    7.14.4. SWOT Analysis
    
    7.14.5. Key Strategies and Developments
    

    8. Assumptions and Acronyms
    
9. Research Methodology
    
10. Contact
  • Inquiry Before Buying

    Inquiry Form

  • Request Sample

    Request for Sample

Related Reports

Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.